Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Analgesics, Opioid | 26 | 2024 | 500 | 5.740 |
Why?
|
| Chronic Pain | 12 | 2024 | 149 | 4.610 |
Why?
|
| Opioid-Related Disorders | 10 | 2023 | 367 | 2.730 |
Why?
|
| Alcoholism | 4 | 2022 | 249 | 2.610 |
Why?
|
| Drug Overdose | 7 | 2023 | 154 | 2.390 |
Why?
|
| Aftercare | 2 | 2023 | 82 | 1.700 |
Why?
|
| Quality of Life | 6 | 2023 | 924 | 1.590 |
Why?
|
| Patient Discharge | 2 | 2023 | 353 | 1.460 |
Why?
|
| Pain | 4 | 2022 | 405 | 1.390 |
Why?
|
| Delivery of Health Care | 3 | 2022 | 325 | 1.030 |
Why?
|
| Substance-Related Disorders | 2 | 2021 | 671 | 0.980 |
Why?
|
| Social Media | 2 | 2023 | 105 | 0.910 |
Why?
|
| Retrospective Studies | 13 | 2024 | 6460 | 0.800 |
Why?
|
| Buprenorphine | 2 | 2022 | 135 | 0.760 |
Why?
|
| Veterans | 5 | 2021 | 619 | 0.760 |
Why?
|
| Humans | 40 | 2024 | 54397 | 0.730 |
Why?
|
| Tramadol | 3 | 2024 | 28 | 0.670 |
Why?
|
| Back Pain | 1 | 2018 | 44 | 0.650 |
Why?
|
| United States | 12 | 2023 | 5209 | 0.630 |
Why?
|
| Osteoarthritis | 1 | 2018 | 69 | 0.620 |
Why?
|
| Hyperalgesia | 1 | 2017 | 56 | 0.580 |
Why?
|
| Arkansas | 7 | 2023 | 2101 | 0.580 |
Why?
|
| Adult | 16 | 2024 | 14210 | 0.560 |
Why?
|
| Safety-Based Drug Withdrawals | 1 | 2015 | 6 | 0.540 |
Why?
|
| Dextropropoxyphene | 1 | 2015 | 5 | 0.540 |
Why?
|
| Aged | 12 | 2023 | 10061 | 0.500 |
Why?
|
| Urban Health Services | 1 | 2014 | 23 | 0.500 |
Why?
|
| Medicare Part D | 1 | 2013 | 6 | 0.460 |
Why?
|
| Financing, Personal | 1 | 2013 | 16 | 0.460 |
Why?
|
| Middle Aged | 13 | 2021 | 13083 | 0.440 |
Why?
|
| Cross-Sectional Studies | 3 | 2023 | 1697 | 0.430 |
Why?
|
| Rural Health Services | 1 | 2014 | 175 | 0.430 |
Why?
|
| Choice Behavior | 1 | 2013 | 95 | 0.420 |
Why?
|
| Mental Health Services | 1 | 2014 | 233 | 0.410 |
Why?
|
| Opiate Substitution Treatment | 2 | 2022 | 80 | 0.390 |
Why?
|
| Students, Pharmacy | 1 | 2013 | 147 | 0.390 |
Why?
|
| Emergency Service, Hospital | 1 | 2015 | 543 | 0.390 |
Why?
|
| Female | 17 | 2023 | 28474 | 0.380 |
Why?
|
| Young Adult | 6 | 2020 | 4319 | 0.370 |
Why?
|
| Male | 15 | 2022 | 27348 | 0.370 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2014 | 389 | 0.360 |
Why?
|
| Depression | 1 | 2014 | 596 | 0.350 |
Why?
|
| Pain Measurement | 2 | 2021 | 248 | 0.330 |
Why?
|
| Propensity Score | 2 | 2018 | 137 | 0.310 |
Why?
|
| Drug Prescriptions | 2 | 2019 | 89 | 0.300 |
Why?
|
| Telemedicine | 2 | 2023 | 453 | 0.290 |
Why?
|
| Databases, Factual | 2 | 2022 | 683 | 0.290 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2020 | 305 | 0.270 |
Why?
|
| Health Services Accessibility | 2 | 2022 | 428 | 0.250 |
Why?
|
| Adolescent | 4 | 2020 | 6901 | 0.230 |
Why?
|
| Rural Population | 3 | 2023 | 598 | 0.230 |
Why?
|
| Hospitals, Urban | 1 | 2023 | 31 | 0.230 |
Why?
|
| Cohort Studies | 2 | 2020 | 1547 | 0.230 |
Why?
|
| Hospitals, Private | 1 | 2022 | 6 | 0.230 |
Why?
|
| Spinal Cord Injuries | 1 | 2023 | 61 | 0.210 |
Why?
|
| Neuralgia | 1 | 2023 | 58 | 0.210 |
Why?
|
| Accidents | 1 | 2021 | 24 | 0.210 |
Why?
|
| Prospective Studies | 2 | 2022 | 2606 | 0.210 |
Why?
|
| Monitoring, Physiologic | 1 | 2022 | 136 | 0.200 |
Why?
|
| Follow-Up Studies | 3 | 2024 | 2390 | 0.200 |
Why?
|
| Socioeconomic Factors | 1 | 2023 | 639 | 0.190 |
Why?
|
| Naloxone | 1 | 2020 | 61 | 0.180 |
Why?
|
| Methamphetamine | 1 | 2022 | 233 | 0.180 |
Why?
|
| Program Evaluation | 1 | 2021 | 379 | 0.170 |
Why?
|
| Hydrocodone | 3 | 2024 | 17 | 0.170 |
Why?
|
| Oxycodone | 3 | 2024 | 24 | 0.170 |
Why?
|
| Narcotic Antagonists | 1 | 2020 | 126 | 0.170 |
Why?
|
| Prescription Drug Misuse | 1 | 2019 | 30 | 0.170 |
Why?
|
| Legislation, Drug | 1 | 2019 | 18 | 0.170 |
Why?
|
| Cost-Benefit Analysis | 2 | 2020 | 291 | 0.170 |
Why?
|
| Prevalence | 2 | 2022 | 1026 | 0.170 |
Why?
|
| Longitudinal Studies | 2 | 2018 | 742 | 0.170 |
Why?
|
| Health Status | 2 | 2018 | 368 | 0.170 |
Why?
|
| Depressive Disorder, Major | 1 | 2020 | 159 | 0.160 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 3431 | 0.160 |
Why?
|
| Odds Ratio | 1 | 2020 | 600 | 0.160 |
Why?
|
| Health Status Indicators | 1 | 2017 | 94 | 0.150 |
Why?
|
| Pyridones | 1 | 2016 | 42 | 0.140 |
Why?
|
| Physicians | 1 | 2019 | 245 | 0.130 |
Why?
|
| Evidence-Based Medicine | 1 | 2017 | 276 | 0.130 |
Why?
|
| Pyrazoles | 1 | 2016 | 110 | 0.130 |
Why?
|
| Warfarin | 1 | 2016 | 87 | 0.130 |
Why?
|
| Brain Ischemia | 1 | 2016 | 169 | 0.120 |
Why?
|
| Veterans Health | 1 | 2014 | 73 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 594 | 0.120 |
Why?
|
| Diabetes Mellitus | 1 | 2017 | 309 | 0.120 |
Why?
|
| Atrial Fibrillation | 1 | 2016 | 197 | 0.110 |
Why?
|
| Anticoagulants | 1 | 2016 | 270 | 0.110 |
Why?
|
| Cost Savings | 1 | 2013 | 67 | 0.110 |
Why?
|
| Risk | 3 | 2020 | 343 | 0.110 |
Why?
|
| Logistic Models | 1 | 2015 | 991 | 0.110 |
Why?
|
| Acetaminophen | 1 | 2015 | 350 | 0.100 |
Why?
|
| Data Collection | 1 | 2013 | 320 | 0.100 |
Why?
|
| Chromans | 1 | 2011 | 62 | 0.100 |
Why?
|
| Patient Satisfaction | 1 | 2013 | 302 | 0.100 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2011 | 119 | 0.100 |
Why?
|
| Cell Death | 1 | 2011 | 223 | 0.100 |
Why?
|
| Vitamin E | 1 | 2011 | 107 | 0.090 |
Why?
|
| Stroke | 1 | 2016 | 526 | 0.090 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2020 | 70 | 0.080 |
Why?
|
| Mitochondria | 1 | 2011 | 490 | 0.080 |
Why?
|
| Neoplasms | 1 | 2018 | 1322 | 0.080 |
Why?
|
| Risk Factors | 3 | 2022 | 3937 | 0.070 |
Why?
|
| Psychometrics | 2 | 2018 | 239 | 0.070 |
Why?
|
| Oxidative Stress | 1 | 2011 | 958 | 0.070 |
Why?
|
| Mental Health | 2 | 2018 | 245 | 0.070 |
Why?
|
| Prescriptions | 1 | 2023 | 9 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 1301 | 0.060 |
Why?
|
| Animals | 2 | 2017 | 14411 | 0.060 |
Why?
|
| Controlled Substances | 1 | 2022 | 4 | 0.060 |
Why?
|
| Capsaicin | 1 | 2023 | 17 | 0.060 |
Why?
|
| Spatial Analysis | 1 | 2022 | 20 | 0.060 |
Why?
|
| Single-Blind Method | 1 | 2023 | 120 | 0.060 |
Why?
|
| Social Class | 1 | 2022 | 109 | 0.050 |
Why?
|
| Medicare | 1 | 2023 | 245 | 0.050 |
Why?
|
| Caregivers | 1 | 2023 | 241 | 0.050 |
Why?
|
| Administration, Intranasal | 1 | 2020 | 29 | 0.050 |
Why?
|
| Markov Chains | 1 | 2020 | 34 | 0.050 |
Why?
|
| Drug Costs | 1 | 2020 | 35 | 0.050 |
Why?
|
| Travel | 1 | 2019 | 30 | 0.040 |
Why?
|
| Risk-Taking | 1 | 2019 | 127 | 0.040 |
Why?
|
| Community Pharmacy Services | 1 | 2020 | 70 | 0.040 |
Why?
|
| Urban Population | 1 | 2019 | 182 | 0.040 |
Why?
|
| Smoking | 1 | 2022 | 553 | 0.040 |
Why?
|
| Pandemics | 1 | 2023 | 594 | 0.040 |
Why?
|
| Acute Pain | 1 | 2017 | 6 | 0.040 |
Why?
|
| Self Report | 1 | 2018 | 205 | 0.040 |
Why?
|
| Thiazoles | 1 | 2016 | 61 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 430 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 643 | 0.030 |
Why?
|
| Comorbidity | 1 | 2017 | 664 | 0.030 |
Why?
|
| Pregnancy | 1 | 2023 | 2641 | 0.030 |
Why?
|
| Insurance, Health | 1 | 2016 | 132 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2016 | 184 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 461 | 0.030 |
Why?
|
| Pyridines | 1 | 2016 | 137 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 1045 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 489 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 1082 | 0.030 |
Why?
|
| tert-Butylhydroperoxide | 1 | 2011 | 6 | 0.030 |
Why?
|
| Oligomycins | 1 | 2011 | 8 | 0.030 |
Why?
|
| Proton-Translocating ATPases | 1 | 2011 | 12 | 0.030 |
Why?
|
| alpha-Tocopherol | 1 | 2011 | 10 | 0.030 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2011 | 48 | 0.030 |
Why?
|
| Cell Respiration | 1 | 2011 | 51 | 0.030 |
Why?
|
| Reactive Nitrogen Species | 1 | 2011 | 37 | 0.030 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2011 | 79 | 0.030 |
Why?
|
| Oxidative Phosphorylation | 1 | 2011 | 57 | 0.030 |
Why?
|
| Rabbits | 1 | 2011 | 425 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2011 | 223 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 2011 | 242 | 0.020 |
Why?
|
| Time Factors | 1 | 2017 | 3210 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2011 | 255 | 0.020 |
Why?
|
| Cell Survival | 1 | 2011 | 657 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2011 | 491 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2011 | 1737 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2017 | 5612 | 0.020 |
Why?
|
| Apoptosis | 1 | 2011 | 1302 | 0.020 |
Why?
|